Glooko, Inc., a globally integrated digital healthcare company focused on helping healthcare systems solve the growing challenges of glycemic safety and diabetes management across care settings, today ...

Prediabetes affects 634.8 million adults globally, i.e., approximately 12% of the adult population (IDF, 2025), with 30.4% ...

Total Revenue -- $164.9 million, up from $157.2 million the previous year; reflects increasing prescriptions and patient volume. Prescription Trends -- Record levels of new prescriptions, new patient ...

A 52-week extension study showed that the drug continues to maintain favorable body composition with no safety issues.

Hypercortisolism is at least as common as hyperaldosteronism, and some people with resistant hypertension have both.

Glooko yesterday announced new data reflecting positive outcomes using its EndoTool platform for insulin dosing.

National nonprofit presents research on intentionally varied peer support and medication adherence at AACE and Society ...

CHARLOTTESVILLE, Va. — A University of Virginia Center for Diabetes Technology-developed algorithm, paired with a continuous glucose monitor, can help users better manage their Type 2 diabetes by ...

Phase 3 trial data show a synthetic semaglutide injection provides glycemic control comparable to Ozempic in patients with ...

LAKEWOOD, CO, UNITED STATES, April 27, 2026 /EINPresswire.com/ -- The American Animal Hospital Association (AAHA) today ...

WAN CHAI, WAN CHAI, HONG KONG, January 23, 2026 /EINPresswire.com/ — Even with the advancement of Automated Insulin Delivery (AID) technologies, diabetes management ...